Bioavailability, Pharmacokinetics, and Analgesic Activity of Ketamine in Humans
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
The pharmacokinetics of ketamine in analgesic doses after intravenous, intramuscular, and oral administration was investigated in healthy volunteers. Plasma ketamine concentration-time curves were fitted by a two-compartment open model with a terminal half-life of 186 min. Absorption after intramuscular injection was rapid and the bioavailability was 93%. However, only 17% of an oral dose was absorbed because of extensive first-pass metabolism. Simultaneous measurements of the elevation of pain threshold in an ischemic exercise test showed a marked effect for 15-60 min after intramuscular injection, but little or no effect after the oral solution. Pain threshold elevation occurred at plasma ketamine concentrations above 160 ng/ml.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Regarding elimination of ketamine and its metabolites, the elimination half-life is between two to four hours, varying slightly with the route of administration”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Clements et al., 1982
Citations
Cites
A Simplex Method for Function Minimization
Nelder, J. A., & Mead, R. (1965) · The Computer Journal · doi:10.1093/comjnl/7.4.308 · Cited by 28,905
TESTING FOR SERIAL CORRELATION IN LEAST SQUARES REGRESSION. II
DURBIN, J., & WATSON, G. S. (1951) · Biometrika · doi:10.1093/biomet/38.1-2.159 · Cited by 3,619
Drugs and the Pharmaceutical Sciences
(2010) · Drugs and the pharmaceutical sciences · doi:10.1201/ihcdruphasci · Cited by 586
New Method for Calculating the Intrinsic Absorption Rate of Drugs
Loo, J. C. K., & Riegelman, S. (1968) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600570602 · Cited by 466
PHARMACOKINETICS AND ANALGESIC EFFECTS OF I.M. AND ORAL KETAMINE
GRANT, I. S., NIMMO, W. S., & CLEMENTS, J. A. (1981) · British Journal of Anaesthesia · doi:10.1093/bja/53.8.805 · Cited by 355
Self-citationPHARMACOKINETICS AND ANALGESIC EFFECT OF KETAMINE IN MAN
CLEMENTS, J. A., & NIMMO, W. S. (1981) · British Journal of Anaesthesia · doi:10.1093/bja/53.1.27 · Cited by 322
Self-citationKETAMINE INFUSIONS: PHARMACOKINETICS AND CLINICAL EFFECTS
IDVALL, J., AHLGREN, I., ARONSEN, K. F., & STENBERG, P. (1979) · British Journal of Anaesthesia · doi:10.1093/bja/51.12.1167 · Cited by 306
Influence of Route of Administration on Drug Availability
Rowland, M. (1972) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600610111 · Cited by 264
Pedersen, P. V. (1977) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01061732 · Cited by 219
Ottaway, J. H. (1973) · Biochemical Journal · doi:10.1042/bj1340729 · Cited by 101
Research works printed but not linked: 9
- Wieber, 1975, Anaesthetist, 24, 260
- Clausen, 1975, Med. J., 49, 1437
- Harrison, 1943, Proc. Assoc. Res. Nerv. Ment. Dis., 23, 154
- Walle, 1970, Acta Pharm. Suec., 7, 389
- Durbin, 1950, Biometrika, 37, 409
- Gibaldi, 1979, Vol. 1, 232
- Rowland, 1972, ibid, 61, 70
- Gibaldi, 1971, ibid., 60, 624
- Pang, 1978, ibid., 67, 703
Cited by
Items 401–418 of 418
A Novel Tertiary Carbamate Prodrug Strategy to Overcome Metabolic Barriers in Oral Ketamine Delivery
Järvinen, J., Adla, S. K., Tampio, J., Jalkanen, A. J., Sloan, K. B., Huttunen, K. M., & Rautio, J. (2026) · ChemMedChem · doi:10.1002/cmdc.202500856
“Traditionally, ketamine is administered intravenously (IV) or intramuscularly (IM) due to its high lipid solubility, rapid blood – brain barrier (BBB) penetration, and relatively short elimination half-life [13 – 17].”
Oral Ketamine for Chronic Pain: Towards an Evidence-Based Dosing Regimen
Winegarden, J. A., Brose, A., Storm, A., Mortensen, A., & Carr, D. B. (2026) · Journal of Pain Research · doi:10.2147/jpr.s545221 · Cited by 1
Bogiel, Z., Machała, A., Bielak, A., Foryś, A., Kałwak, M., Kuczwalska, D., Spychalska, M., & Trocka, D. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.4600
Horowitz, R. K., Rosa, W. E., Zarrabi, A. J., & Swogger, M. T. (2026) · Journal of Palliative Medicine · doi:10.1177/10966218251392787
“IM administration achieves high and consistent bioavailability ( * 93%), 115 with predictable onset and duration.”
Prise en charge médicamenteuse des patients souffrant de douleur chronique réfractaire
Corriger, A. (2019) · theses.fr (ABES) · doi:10.70675/668e4777zf8d0z4bdcz9780z0f91fedfe2b6
Costa, B. M., Davis, J. L., Hines, D., Anandakrishnan, R., & Tuohy, J. L. (2026) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2026.104787 · Cited by 1
Advances in Psychopharmacology: What Clinicians Need to Know
(2026) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.26024109
Neuroscientific Basis of Ketamine as an Analgesic and Emerging Role in the Management of Depression
Coggins, N., Chokr, H. A., Meyer, T. A., Patel, M., Shekoohi, S., & Kaye, A. D. (2026) · Current Pain and Headache Reports · doi:10.1007/s11916-026-01475-7
Channabasappa, S., Singh, G., Chokhsi, T., & Bajwa, S. S. (2026) · Indian Journal of Anaesthesia · doi:10.4103/ija.ija_675_26
“Fixed parameters; no age or weight adjustment Clements 250 (1982) [8,9] None (fixed) Hannivoort (2015) [3] Weight (allometric) [4,5] Age, weight, fat-free mass”
Intramuscular Ketamine Pharmacokinetics in Humans: A Review
Ananyev, J., & Myers, T. M. (2026) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-026-01012-2
“…± 2.0 years old; 70.7 ± 4.4 kg), administering IM ketamine in the triceps muscle at a dose of 0.5 mg/kg and using a two compartment model: C max (240 ± 50 ng/mL [36] or 243 ± 49 ng/mL [40]), t max (22 ± 4 min [36, 40]), bioavailability (93.0 ± 2.6% [36, 40]), and AUC (23.6 ± 2.2 ng × min/mL [40]).”
InfluentialYang, S., Wang, L. J., Sun, Y., Ma, X. Y., Rong, Y., Fong, T. H., Li, T., Deng, D., Li, X.-X., Zhang, Z., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.31.727553
Angel, M. (2026) · Case Reports in Psychiatry · doi:10.1155/crps/6450306
Kallarackal, J., Dyer, B. J., & Huang, J. (2026) · Springer eBooks · doi:10.1007/978-3-032-25214-2_36
Hao, J., Yang, H., Hu, Y., Wu, R., & Luo, K. Q. (2026) · Journal of Applied Toxicology · doi:10.1002/jat.70438
Jones, J. L., Redding, J., & Amador, E. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261488486
Olivola, M., Martiadis, V., Prodi, T., Anniverno, R., Dell’Osso, B. M., Zizzi, A., Facchinetti, E. L., Serafini, G., & Guglielmo, R. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-026-04197-2
“In adults, oral ketamine undergoes extensive first-pass metabolism: bioavailability was 17% after racemic ketamine [35], and oral S-ketamine showed poor bioavailability with increased exposure to active metabolites [36].”
Varun, T. M., Deodhar, J. K., Thota, R. S., Kuriakose, J., Kamble, S. S., Shah, I. J., & Ajithkumar, A. (2026) · Indian Journal of Palliative Care · doi:10.25259/ijpc_435_2025
Liver Disease and Liver Transplantation
Neelakanta, G., & Xia, V. W. (2014) · Springer eBooks · doi:10.1007/978-1-4614-8948-1_44
Metadata
- Authors
- Clements, J. A., Nimmo, W. S., & Grant, I. S.
- Affiliations
- Heriot-Watt University (GB)
- Western Infirmary (GB)
- Corresponding author
- Clements, J.A.
- ORCID
- Grant, I.S.
- Venue
- Journal of Pharmaceutical Sciences
- Publisher
- Elsevier BV
- Published
- 1982-05
- Volume
- 71
- Issue
- 5
- Pages
- 539-542
- ISSN
- 0022-3549 (ISSN-L)
- OpenAlex
- W2094496261
- Cited by
- 420
- References
- 20
- Citations by year
- 2026: 20 · 2025: 25 · 2024: 17 · 2023: 20 · 2022: 34 · 2021: 17 · 2020: 50 · 2019: 11 · 2018: 20 · 2017: 13 · 2016: 20 · 2015: 16 · 2014: 21 · 2013: 16 · 2012: 10
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Journal of Pharmaceutical Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Sedative Agents
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Pain Management
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- ketamine, pharmacokinetics, bioavailability, analgesia, pain threshold, first-pass metabolism, intramuscular injection, oral administration, intravenous administration, two-compartment model, terminal half-life
- MeSH terms
- Administration, Oral, Adult, Analgesics, Biological Availability, Physical Exertion, Humans, Injections, Intramuscular, Injections, Intravenous, Ketamine, Kinetics, Pain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.